GB0226595D0 - Cancer therapy determination - Google Patents
Cancer therapy determinationInfo
- Publication number
- GB0226595D0 GB0226595D0 GBGB0226595.7A GB0226595A GB0226595D0 GB 0226595 D0 GB0226595 D0 GB 0226595D0 GB 0226595 A GB0226595 A GB 0226595A GB 0226595 D0 GB0226595 D0 GB 0226595D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer therapy
- therapy determination
- determination
- cancer
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226595.7A GB0226595D0 (en) | 2002-11-15 | 2002-11-15 | Cancer therapy determination |
| PCT/EP2003/012245 WO2004042080A1 (en) | 2002-11-05 | 2003-11-03 | Cancer therapy determination |
| AU2003283339A AU2003283339A1 (en) | 2002-11-05 | 2003-11-03 | Cancer therapy determination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226595.7A GB0226595D0 (en) | 2002-11-15 | 2002-11-15 | Cancer therapy determination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0226595D0 true GB0226595D0 (en) | 2002-12-24 |
Family
ID=9947830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0226595.7A Ceased GB0226595D0 (en) | 2002-11-05 | 2002-11-15 | Cancer therapy determination |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003283339A1 (en) |
| GB (1) | GB0226595D0 (en) |
| WO (1) | WO2004042080A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL217731B1 (en) * | 2006-06-01 | 2014-08-29 | Tomasz Byrski | Detection of lowered response for chemotherapy with the use of cytostatics from a group of toxoids |
| PL212012B1 (en) * | 2008-07-06 | 2012-07-31 | Tomasz Byrski | Detection of existence of increased risk of chemotherapy side effects by the use of platinum cytostatics |
| WO2010037224A1 (en) * | 2008-10-03 | 2010-04-08 | St. Michael's Hospital | Method for preventing and treating cardiovascular diseases with brca1 |
| ES2704303T3 (en) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedures for the prediction of a response against cancer |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| US20180148792A1 (en) * | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030165956A1 (en) * | 2002-01-25 | 2003-09-04 | Board Of Regents, The University Of Texas System | Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy |
-
2002
- 2002-11-15 GB GBGB0226595.7A patent/GB0226595D0/en not_active Ceased
-
2003
- 2003-11-03 WO PCT/EP2003/012245 patent/WO2004042080A1/en not_active Ceased
- 2003-11-03 AU AU2003283339A patent/AU2003283339A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004042080A1 (en) | 2004-05-21 |
| AU2003283339A1 (en) | 2004-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1482970A4 (en) | Cancer therapy | |
| IL251270A0 (en) | Cancer treatment | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| EP1572131A4 (en) | Antibody therapy | |
| AU2003235470A8 (en) | Predictive markers in cancer therapy | |
| EP1581244A4 (en) | Novel therapeutic targets in cancer | |
| GB0218526D0 (en) | Combination therapy | |
| IL174871A0 (en) | Compounds for dual photodiagnosis and therapy | |
| AU2003212634A8 (en) | Compounds useful in the treatment of cancer | |
| GB0326578D0 (en) | Cancer diagnosis and therapy | |
| GB0226595D0 (en) | Cancer therapy determination | |
| AU2003231803A8 (en) | Treatment of cancer with mefloquire | |
| GB0223325D0 (en) | Treating cancer | |
| EP1463511A4 (en) | Combination cancer therapy | |
| GB2383538B (en) | Cancer treatment | |
| AU2003238722A8 (en) | Cancer therapy by modulating cdc42-activity | |
| GB0303289D0 (en) | Combination therapy | |
| GB0213474D0 (en) | Tumour therapy | |
| GB0218725D0 (en) | Cancer related methods | |
| GB0207031D0 (en) | Treating cancer | |
| GB0220841D0 (en) | Therapy | |
| GB0230027D0 (en) | Therapy | |
| GB0218388D0 (en) | Combination therapy | |
| GB0212396D0 (en) | Combination therapy | |
| GB0218525D0 (en) | Combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |